Q2 2026
Company Update
Mesoblast posted $115 million in first-year Ryoncil revenue, crushing the $52 million estimate, but the full-year tally obscures a stunning second-half acceleration that sent $66.5 million in sales through the door as the cell therapy gained traction across major pediatric transplant centers. The biotech has nearly three years of runway on $103 million in cash before burning through its fuel, buying time for adult label extensions and a Duchenne muscular dystrophy registrational trial to potentially unlock blockbuster potential.
